☆ 4.5 Review

Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Radiology, Nuclear Medicine & Medical Imaging

PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0

Wolfgang P. Fendler et al.

Summary: This article aims to provide updated guidance and standards for the use of PSMA PET/CT in imaging prostate cancer. It discusses procedures and characteristics of various PSMA small radioligands and different clinical scenarios for their use. The document is intended to support clinicians and technicians in implementing PSMA PET/CT imaging in both research and routine practice.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Application of the long axial field-of-view PET/CT with low-dose [18F]FDG in melanoma

Christos Sachpekidis et al.

Summary: The study aims to determine an appropriate acquisition time range for the new long axial field of view Biograph Vision Quadra PET/CT scanner in melanoma patients. The results show that low-dose LAFOV PET/CT imaging is feasible and can provide comparable diagnostic data to standard lengths of acquisition in a shorter scanning time, which is significant for the diagnostic work-up of melanoma patients.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Is 18F-FDG PET Needed to Assess 177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis

Robert Seifert et al.

Summary: This study aimed to reanalyze patients who underwent both 18F-FDG and PSMA PET to assess their eligibility for PSMA-targeted therapy. The results showed that less than 5% of patients had mismatch findings between 18F-FDG and PSMA PET not detected by PSMA PET-only analysis. Based on these data, there is a substantial level of agreement between the 18F-FDG/PSMA mismatch examination and PSMA-only analysis.

JOURNAL OF NUCLEAR MEDICINE (2023)

添加到收藏夹

Article Medicine, Research & Experimental

Gene's expression underpinning the divergent predictive value of [18F]F-fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in primary prostate cancer: a bioinformatic and experimental study

Matteo Bauckneht et al.

Summary: This study investigated the independent and additive prognostic value of PSMA and FDG gene expression in risk-stratification of prostate cancer (PCa). Machine learning analysis identified a predictive functional network involving glucose metabolism-related genes. Cellular experiments showed that increased proliferation and migration of PCa cells were associated with enhanced FDG uptake and decreased PSMA retention, indicating the prognostic value of FDG PET imaging.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

添加到收藏夹

Review Medicine, General & Internal

PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications

Aadil Adnan et al.

Summary: Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is up-regulated in prostate carcinoma and other benign and malignant conditions. PSMA PET-CT has been approved for the diagnosis of high-risk and biochemically recurrent prostate carcinoma and for patient selection for PSMA based theranostics. This review discusses the clinical evolution of PSMA molecule, indications of PSMA PET-CT, appropriateness criteria, pitfalls and artefacts, and other uses of PSMA PET beyond prostate carcinoma.

DIAGNOSTICS (2023)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy

Ian Alberts et al.

Summary: Adding a low-dose 2-[F-18]FDG PET/CT as part of a same-day imaging protocol is feasible and can help detect lesions with low PSMA expression and play a role in therapy assessment.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

添加到收藏夹

Review Oncology

Radiotheranostics in oncology: Making precision medicine possible

Eric O. Aboagye et al.

Summary: Theranostics is a rapidly evolving field of medicine that combines diagnosis and treatment using similar tools. It offers the potential for high therapeutic efficacy with minimal toxicity. In oncology, theranostics relies on the identification of unique proteins and factors expressed in cancer cells, advances in imaging technology, and targeted chemicals and nanodevices for imaging and therapy. Radiotheranostics, using radiopharmaceuticals, is becoming routine in prostate cancer and neuroendocrine tumors. Although not all patients benefit from radiotheranostics, those who do often show high response rates.

CA-A CANCER JOURNAL FOR CLINICIANS (2023)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

A systematic review for using deep learning in bone scan classification

Yung-Shuo Kao et al.

Summary: This systematic review evaluates the use of deep learning models in bone scan classification and concludes that they have strong potential for clinical diagnosis assistance.

CLINICAL AND TRANSLATIONAL IMAGING (2023)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Detection efficacy of analog [18F]FDG PET/CT, digital [18F]FDG, and [13N]NH3 PET/CT: a prospective, comparative study of patients with lung adenocarcinoma featuring ground glass nodules

Zhifeng Chen et al.

Summary: This study compared the detection efficacy of different types of PET/CT for lung adenocarcinoma with GGNs. It found that dF PET/CT had better detection performance compared to aF PET/CT, especially in mGGNs. Additionally, dN PET/CT had better detection performance compared to dF PET/CT, particularly in pGGNs.

EUROPEAN RADIOLOGY (2023)

添加到收藏夹

Article Oncology

Molecular imaging in oncology: Current impact and future directions

Steven P. Rowe et al.

Summary: Molecular imaging, defined as visualizing, characterizing, and measuring biological processes at the molecular and cellular levels, has rapidly developed in recent years, with a particular focus on oncology for early detection and optimal disease management. The expansion of molecular imaging is driven by new animal models, sensitive imaging devices, high-throughput methods, genetic manipulation techniques, and cloud computing. Researchers and clinicians are utilizing molecular imaging for a variety of physiological processes, with a focus on oncology for its potential in detecting diseases at an early stage.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Review Oncology

State of the art of radiomic analysis in the clinical management of prostate cancer: A systematic review

Samuele Ghezzo et al.

Summary: This study reviews the clinical applications of radiomics in prostate cancer management, including detection, clinical significance assessment, biochemical recurrence prediction, radiation-therapy outcome prediction, metastases detection and prediction, and extra-prostatic extension prediction. Seventy-six studies were analyzed qualitatively, showing promising results in discriminating between healthy tissue and cancer, as well as between low- and high-risk prostate cancer. Standardization of radiomics methods and replication of results in large and independent cohorts are needed before clinical use.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

The Added Value of 18F-FDG PET/CT Compared with 68Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer

Ruohua Chen et al.

Summary: The diagnostic efficiency of Ga-68-PSMA PET/CT and F-18-FDG PET/CT in CRPC patients was compared, and it was found that patients with high Gleason score and PSA may benefit from additional F-18-FDG PET/CT.

JOURNAL OF NUCLEAR MEDICINE (2022)

添加到收藏夹

Review Oncology

Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives

Luca Urso et al.

Summary: PSMA PET/CT in Renal Cell Carcinoma: A Review. This review provides an updated overview of the current evidence and major limitations regarding the use of PSMA PET/CT in renal cell carcinoma. The findings suggest that PSMA PET/CT could be a valuable imaging option for diagnosis, staging, and therapy response evaluation in renal cell carcinoma, particularly in clear cell RCC.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Genetics & Heredity

Lutetium Lu 177 Vipivotide Tetraxetan: First Approval

Susan J. Keam

Summary: Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent for the treatment of metastatic prostate cancer expressing PSMA. It has been approved in the USA and is undergoing regulatory review in other countries.

MOLECULAR DIAGNOSIS & THERAPY (2022)

添加到收藏夹

Review Oncology

PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature

Pierpaolo Alongi et al.

Summary: This article systematically reviews the role of radiolabeled choline and PSMA PET in the assessment of prostate cancer. It highlights the prognostic importance of radiolabeled choline and PSMA-11 in the evaluation of response to therapy. However, the role of these new-generation imaging techniques in systemic therapy is still controversial and requires further research support.

CANCERS (2022)

添加到收藏夹

Article Multidisciplinary Sciences

The ImSURE phantoms: a digital dataset for radiomic software benchmarking and investigation

Andrea Bettinelli et al.

Summary: Radiomic models are an important tool in predicting clinical outcomes in radiology and oncology, but lack of standardisation has hindered their clinical deployment. The Image Biomarker Standardisation Initiative aims to provide guidelines and digital phantoms for software calibration. The ImSURE phantoms offer additional features for assessing the concordance of radiomic software.

SCIENTIFIC DATA (2022)

添加到收藏夹

Review Medicine, General & Internal

PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?

Chiara Lauri et al.

Summary: The expanding use of PSMA imaging for prostate cancer has led to the incidental detection of extra-prostatic malignancies. Despite the lack of specificity to the prostate gland, this presents an opportunity to gain new insights into the biology of PSMA and its sites of expression, particularly in cancer imaging and treatment.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Oncology

Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA

Majid Assadi et al.

Summary: This study investigated the predictive values of volumetric parameters and radiomic features extracted from pretreatment 68Ga-PSMA PET and clinical parameters in response to 177Lu-PSMA therapy in mCRPC patients. The results showed significant correlations between certain parameters and biochemical response and overall survival. Some parameters also demonstrated good performance in predicting therapy response.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Radiotheranostics in oncology: current challenges and emerging opportunities

Lisa Bodei et al.

Summary: Radiotheranostics, combining molecular imaging with targeted radionuclide therapy, has great potential and faces various challenges. It offers a huge opportunity in oncology to improve treatment outcomes and minimize side effects.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Baseline Imaging Derived Predictive Factors of Response Following [Lu-177]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis

Esmee C. A. van der Sar et al.

Summary: This study investigated the predictive ability of PET/CT imaging factors before and after [Lu-177]Lu-PSMA-617 treatment in metastatic castration resistant prostate cancer patients. The study found that SUVpeak of the most avid lesion was the key factor in predicting the imaging-based response at the patient-level.

BIOMEDICINES (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

PET-Derived Radiomics and Artificial Intelligence in Breast Cancer: A Systematic Review

Luca Urso et al.

Summary: Breast cancer is a major cause of death among women, but the heterogeneity of the disease makes it challenging to identify valuable biomarkers and optimal treatment approaches. Radiomics and artificial intelligence have shown promise in detecting previously unseen features in medical images of breast cancer, aiding in staging, prognosis, and biological assessment. However, larger prospective trials are needed to confirm and standardize the application of these new techniques in breast cancer.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Oncology

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, 2 trial

James P. Buteau et al.

Summary: This study analyzed the predictive and prognostic value of gallium-68 [(68Ga)68Ga]Ga-PSMA-11 PET and 2-[18F]fluoro-2-deoxy-D-glucose PET imaging parameters in men with metastatic castration-resistant prostate cancer.

LANCET ONCOLOGY (2022)

添加到收藏夹

Review Oncology

PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?

Alessio Rizzo et al.

Summary: Positron Emission Tomography/Computed Tomography (PET/CT) plays an important role in the management of oncological patients, and prostate-specific membrane antigen (PSMA) radioligands are effective targets for molecular imaging and radioligand therapy (RLT). PSMA radioligand PET shows promising performance in non-prostate solid tumors, but further research is needed to explore its potential role in oncological patients management.

CANCERS (2022)

添加到收藏夹

Review Oncology

Bone Health Management in the Continuum of Prostate Cancer Disease

Ettickan Boopathi et al.

Summary: This review summarizes the risk factors, mechanism, current treatments, side-effects, management of skeletal-related events, and potential therapeutic options for bone management in prostate cancer-induced bone metastasis. Prostate cancer is the second-leading cause of cancer-related deaths in men, and bone metastases are common in the disease progression. Current diagnostics and treatment options are not accurate or efficient enough to manage bone health in patients with bone metastases.

CANCERS (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial

Luca Urso et al.

Summary: This study aimed to evaluate the changes in FDG PET in neuroendocrine neoplasms (NENs) patients treated with different radioligand therapy (RLT) schemes and correlate them with clinical-pathologic variables. The results suggest that RLT, especially with the DUO scheme, could effectively change the glycometabolism of NEN lesions, particularly in pancreatic and CUP-NEN patients. Further studies are needed to validate these preliminary findings.

PHARMACEUTICS (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Theragnostic Radionuclide Pairs for Prostate Cancer Management: 64Cu/67Cu, Can Be a Budding Hot Duo

Anupriya Chhabra et al.

Summary: This article discusses the potential of theragnostic radionuclide pairs for the management of prostate cancer, with a special emphasis on the emerging theragnostic radionuclide pair, Copper-64/Copper-67 (Cu-64/Cu-67).

BIOMEDICINES (2022)

添加到收藏夹

Review Oncology

[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature

Laura Evangelista et al.

Summary: This systematic review analyzed the available literature on [Ga-68] and [F-18]-labeled prostate-specific membrane antigen and identified the advantages and disadvantages of different tracers for the management of patients with prostate cancer. The findings suggest that specific clinical indications may influence the choice of tracer preference.

EUROPEAN UROLOGY ONCOLOGY (2022)

添加到收藏夹

Article Engineering, Biomedical

Digital PET/CT with 18F-FACBC in early castration-resistant prostate cancer: our preliminary results

Luca Filippi et al.

Summary: Digital PET/CT with F-18-FACBC was evaluated in patients with early castration-resistant prostate cancer, and it was found that F-18-FACBC dPET/CT can detect M1 metastasis in 33.3% of patients, significantly impacting clinical management.

EXPERT REVIEW OF MEDICAL DEVICES (2022)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

ImmunoPET for prostate cancer in the PSMA era: do we need other targets?

Luca Filippi et al.

Summary: Prostate specific membrane antigen (PSMA) plays a crucial role in prostate cancer management, but it is absent or lowly expressed in some cases. ImmunoPET imaging has identified new biomarkers, such as PSCA and DLL3, which show promise as potential targets for therapy and diagnosis. Other biomarkers, including VEGFR-2 and CD46, have also been explored through immunoPET in pre-clinical studies. These immunoPET pre-clinical studies have high impact on the development of prostate cancer theranostics.

CLINICAL AND TRANSLATIONAL IMAGING (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?

Luca Urso et al.

Summary: [18F]F-choline PET plays an important role in evaluating the response to systemic therapy in prostate cancer patients, regardless of the disease stage and treatment type. It can serve as a useful imaging modality to assess disease progression.

CLINICAL AND TRANSLATIONAL IMAGING (2022)

添加到收藏夹

Review Urology & Nephrology

Radiomics in prostate cancer: an up-to-date review

Matteo Ferro et al.

Summary: This article provides an overview of the application of radiomics in prostate cancer patients, emphasizing its potential for personalized treatment and future applications.

THERAPEUTIC ADVANCES IN UROLOGY (2022)

添加到收藏夹

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Urology & Nephrology

The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol

Frederic Pouliot et al.

Summary: This study aims to investigate intra-patient inter-metastatic heterogeneity in mCRPC patients using a triple-tracer PET/CT strategy, to understand the phenotypic plasticity of prostate cancer, including neuroendocrine transdifferentiation. Eligibility for PSMA and DOTATATE-based radioligand therapies will be assessed based on PET findings.

BJU INTERNATIONAL (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Kerstin Michalski et al.

Summary: The study found that patients with at least one FDG+/PSMA- lesion had significantly lower overall survival, while patients without any FDG+/PSMA- lesions had higher overall survival. FDG+/PSMA- lesions may serve as a negative predictor for overall survival in mCRPC patients undergoing RLT.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Urology & Nephrology

Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA

Benedikt Feuerecker et al.

Summary: Ac-225-PSMA-617 demonstrated measurable antitumor effect in late-stage mCRPC after Lu-177-PSMA failure. Grade 3/4 hematological side effects were observed in up to one-third of patients, and xerostomia led to treatment halt in a relevant number of patients.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Article Oncology

18F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases

Kalevi Kairemo et al.

Summary: Patients with osteoblastic metastases from high risk osteosarcoma have a poor prognosis after standard-of-care multi-agent chemotherapy. A dose escalation trial of bone targeted Radium 223 dichloride alpha-particle therapy showed only 1 patient responding based on conventional RECIST criteria, leading to the development of NAFCIST criteria and radiomics method for better evaluation of bone specific response. Analysis of F-18-sodium fluoride PET imaging studies revealed intra-tumoral and inter-tumoral heterogeneity in response to alpha particle therapy.

CURRENT PROBLEMS IN CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman et al.

Summary: [Lu-177]Lu-PSMA-617 showed a higher PSA response and fewer grade 3-4 adverse events compared to cabazitaxel in men with metastatic castration-resistant prostate cancer.

LANCET (2021)

添加到收藏夹

Review Oncology

Additional Value of PET Radiomic Features for the Initial Staging of Prostate Cancer: A Systematic Review from the Literature

Priscilla Guglielmo et al.

Summary: Prostate cancer (PCa) is a common malignancy in men with prognosis depending on staging at diagnosis. Molecular imaging techniques like PET/CT or PET/MRI, using prostate-specific radiotracers, are increasingly used for accurate evaluation of PCa staging and providing non-invasive and longitudinal biomarkers for personalized medicine.

CANCERS (2021)

添加到收藏夹

Review Oncology

Radiomics for Identification and Prediction in Metastatic Prostate Cancer: A Review of Studies

Jake Kendrick et al.

Summary: Metastatic Prostate Cancer (mPCa) presents challenges in clinical management due to its spread throughout the body, particularly to bones. Radiomics methods offer quantification of disease spread, yet current limitations, like limited reproducibility, hinder their clinical translation.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Decision-support for treatment with 177Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET/CT and clinical parameters

Sobhan Moazemi et al.

Summary: This study investigated the role of radiomics features in PSMA-PET/CT scans and clinical parameters to predict response to Lu-177-PSMA treatment using machine learning methods. The results showed that specific radiomics features and clinical parameters had significant correlations with treatment response. Machine learning based on Ga-68-PSMA PET/CT radiomics features shows promise for predicting response to Lu-177-PSMA treatment.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Review Oncology

Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer

Nicholas Mitsiades et al.

Summary: Hormonal therapies have been effective for treating advanced prostate cancer for decades, but issues with androgen receptor axis inhibition have led to clinical resistance. Recent advancements in androgen receptor signaling inhibitors have shown benefits for patients and validated important concepts proposed in the past.

ENDOCRINE-RELATED CANCER (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging

Hannes Gruenig et al.

Summary: Improved logistics and availability have led to a rapid increase in the use of [F-18]-PSMA-1007 for prostate cancer PET imaging. Initial data suggest increased uptake in benign lesions compared to [(68)Ga]-PSMA-11, and clinical observations found increased unspecific bone uptake (UBU). UBUs occur in two-thirds of patients imaged with [F-18]-PSMA-1007 PET/CT and are significantly more frequent on digital PET scanners than analog scanners, highlighting the need for careful interpretation to avoid over-staging.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy

Sandy Srinivas et al.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor et al.

Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Oncology

PSMA Theranostics: Current Landscape and Future Outlook

Hanbo Zhang et al.

Summary: The prognosis for metastatic prostate cancer patients remains poor, but PSMA-targeted imaging and therapy show promise as a potential standard of care. PSMA is a novel molecular target that may alter the natural history of prostate cancer, with a growing body of evidence supporting its use in theranostic approaches.

CANCERS (2021)

添加到收藏夹

Article Oncology

Evaluation of 68Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving 177Lu-PSMA-617 Therapy: A Radiomics Analysis

Wolfgang Roll et al.

Summary: This study analyzed the predictive and prognostic value of radiomic features from pretherapeutic PSMA PET-MRI and Ga-68-PSMA-11 PET-MRI in advanced prostate cancer patients undergoing PSMA therapy. The radiomic analysis revealed that the interquartile range feature from T2-weighted images showed the highest accuracy in predicting treatment response and survival outcomes.

CANCERS (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

90Y/177Lu-DOTATOC: From Preclinical Studies to Application in Humans

Licia Uccelli et al.

Summary: PRRT is a promising treatment for inoperable or metastatic NETs patients, with good PFS and OS compared to standard therapies. The somatostatin-modified peptide fragment [Tyr3] octreotide equipped with a specific chelating system DOTA is crucial in creating stable bonds with beta-emitting radionuclides like yttrium-90 and lutetium-177. The review covers twenty-five years of literature and describes the characteristics and performances of the two most used therapeutic radiopharmaceuticals for NETs radiotherapy: [Y-90]Y-DOTATOC and [Lu-177]Lu-DOTATOC.

PHARMACEUTICS (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Current and future perspectives on functional molecular imaging in nephro-urology: theranostics on the horizon

Yoshitaka Toyama et al.

Summary: In recent years, there has been a paradigm shift in nuclear oncology from single-photon-emitting radionuclide radiotracers to positron-emission tomography (PET) radiotracers. PET radionuclide imaging for kidneys, although still in its infancy, offers precise anatomical co-registration with CT images and dynamic three-dimensional imaging capabilities. Additionally, PET reduces scan time and radiation exposure compared to scintigraphic approaches, potentially impacting clinical practice in pediatric populations.

THERANOSTICS (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients

Madhav Prasad Yadav et al.

CLINICAL NUCLEAR MEDICINE (2020)

添加到收藏夹

Article Oncology

Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223

Matteo Bauckneht et al.

CANCERS (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients

Giovanni Paganelli et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)

添加到收藏夹

Review Chemistry, Multidisciplinary

PET/CT Radiomics in Lung Cancer: An Overview

Francesco Bianconi et al.

APPLIED SCIENCES-BASEL (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors

Andrea Cimini et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Engineering, Biomedical

Aptamer-based technology for radionuclide targeted imaging and therapy: a promising weapon against cancer

Luca Filippi et al.

EXPERT REVIEW OF MEDICAL DEVICES (2020)

添加到收藏夹

Review Oncology

Immunotherapy in Prostate Cancer

Emily K. Fay et al.

CANCERS (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer

Wen-Ting K. Tsai et al.

MOLECULAR IMAGING AND BIOLOGY (2020)

添加到收藏夹

Article Oncology

The potential of PSMA-targeted alpha therapy in the management of prostate cancer

Luca Filippi et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Prognostic Value of 18F-Choline PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223

Luca Filippi et al.

BIOMEDICINES (2020)

添加到收藏夹

Article Oncology

Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

Louise Emmett et al.

CLINICAL GENITOURINARY CANCER (2019)

添加到收藏夹

Article Oncology

Neuroendocrine differentiation of prostate cancer leads to PSMA suppression

Martin K. Bakht et al.

ENDOCRINE-RELATED CANCER (2019)

添加到收藏夹

Letter Radiology, Nuclear Medicine & Medical Imaging

Radiomic Machine Learning: Is It Really a Useful Method for the Characterization of Prostate Cancer?

Michele Scialpi et al.

RADIOLOGY (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis

Mari Suominen et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹

Article Oncology

Imaging-Based Individualized Response Prediction Of Carbon Ion Radiotherapy For Prostate Cancer Patients

Shuang Wu et al.

CANCER MANAGEMENT AND RESEARCH (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer

Thorsten D. Poeppel et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Uptake of Radium-223 Dichloride and Early [18F]NaF PET Response Are Driven by Baseline [18F]NaF Parameters: a Pilot Study in Castration-Resistant Prostate Cancer Patients

Arthur Letellier et al.

MOLECULAR IMAGING AND BIOLOGY (2018)

添加到收藏夹

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion

Kambiz Rahbar et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)

添加到收藏夹

Article Oncology

Yttrium-90 resin microspheres and their use in the treatment of intrahepatic cholangiocarcinoma

Luca Filippi et al.

FUTURE ONCOLOGY (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Profiling Prostate Cancer Therapeutic Resistance

Cameron A. Wade et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies

Denise S. O'Keefe et al.

JOURNAL OF NUCLEAR MEDICINE (2018)

添加到收藏夹

Article Oncology

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S. Hofman et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience

Kalevi Kairemo et al.

CURRENT RADIOPHARMACEUTICALS (2018)

添加到收藏夹

Article Computer Science, Theory & Methods

Big healthcare data: preserving security and privacy

Karim Abouelmehdi et al.

JOURNAL OF BIG DATA (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE

Maddalena Sansovini et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617

Justin Ferdinandus et al.

JOURNAL OF NUCLEAR MEDICINE (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617

Hojjat Ahmadzadehfar et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer

Iain Murray et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding

Clemens Kratochwil et al.

JOURNAL OF NUCLEAR MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

J. Strosberg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Oncology

Technical Challenges in the Clinical Application of Radiomics

Faiq A. Shaikh et al.

JCO CLINICAL CANCER INFORMATICS (2017)

添加到收藏夹

Review Gastroenterology & Hepatology

Theranostics of Neuroendocrine Tumors

Sze Ting Lee et al.

VISCERAL MEDICINE (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Molecular response assessed by 68Ga-DOTANOC and survival after 90Y microsphere therapy in patients with liver metastases from neuroendocrine tumours

Luca Filippi et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride

Massimiliano Pacilio et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy

Elba C. Etchebehere et al.

CLINICAL NUCLEAR MEDICINE (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Repeatability of Quantitative 18F-NaF PET: A Multicenter Study

Christie Lin et al.

JOURNAL OF NUCLEAR MEDICINE (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer

Andrei H. Iagaru et al.

JOURNAL OF NUCLEAR MEDICINE (2016)

添加到收藏夹

Review Medicine, Research & Experimental

64Cu2+ Ions as PET Probe: An Emerging Paradigm in Molecular Imaging of Cancer

Rubel Chakravarty et al.

MOLECULAR PHARMACEUTICS (2016)

添加到收藏夹

Article Urology & Nephrology

VPAC1 Targeted 64Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man

Sushil Tripathi et al.

UROLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT

Kalevi Kairemo et al.

DIAGNOSTICS (2015)

添加到收藏夹

Article Oncology

Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis-A Systematic Review and Pooled Analysis

Hai Tao Wang et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

Skeletal SPECT/CT: a review

Torsten Kuwert

CLINICAL AND TRANSLATIONAL IMAGING (2014)

添加到收藏夹

Article Medicine, General & Internal

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

C. Parker et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy

Shinji Kurosaka et al.

ANNALS OF NUCLEAR MEDICINE (2012)

添加到收藏夹

Article Oncology

Radiomics: Extracting more information from medical images using advanced feature analysis

Philippe Lambin et al.

EUROPEAN JOURNAL OF CANCER (2012)

添加到收藏夹

Article Oncology

18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors

Tina Binderup et al.

CLINICAL CANCER RESEARCH (2010)

添加到收藏夹

Article Oncology

Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms

Jinlu Dai et al.

CANCER RESEARCH (2008)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Skeletal PET with F-18-fluoride: Applying new technology to an old tracer

Frederick D. Grant et al.

JOURNAL OF NUCLEAR MEDICINE (2008)

添加到收藏夹

Article Engineering, Biomedical

SPECT/CT with a hybrid camera: a new imaging modality for the functional anatomical mapping of infections

Luca Filippi et al.

EXPERT REVIEW OF MEDICAL DEVICES (2006)

添加到收藏夹

Article Oncology

Intraoperative gamma probe detection of head and neck paragangliomas with 111In-pentetreotide:: A pilot study

L Filippi et al.

TUMORI JOURNAL (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.